Newsfeeds - Spark Newswire

1 minute read

Earnings

INVO Bioscience: Q1 Earnings Insights

Today, 7:08 PM

INVO Bioscience (NASDAQ:INVO) reported its Q1 earnings results on Monday, May 16, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings INVO Bioscience beat estimated earnings by 8.0%, reporting an EPS of $-0.23 versus an estimate of $-0.25.

INVO

1 minute read

INVO Bioscience Q1 EPS $(0.23) Up From $(0.25) YoY, Sales $162.60K Down From $684.52K YoY

By Benzinga Newsdesk

Today, 7:08 PM

INVO Bioscience (NASDAQ:INVO) reported quarterly losses of $(0.23) per share. This is a 8 percent increase over losses of $(0.25) per share from the same period last year. The company reported $162.60 thousand in sales

INVO

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights

Today, 7:08 PM

Gainers

ASLN

10 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 7:08 PM

On Wednesday, 160 companies hit new 52-week lows.

ACLX

15 minute read

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 7:08 PM

On Tuesday, 242 companies hit new 52-week lows.

ACRX

5 minute read

Earnings Scheduled For March 31, 2022

By Benzinga Insights

Today, 7:08 PM

Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.

ACTG

1 minute read

Earnings

INVO Bioscience Earnings Preview

By Benzinga Insights

Today, 7:08 PM

INVO Bioscience (NASDAQ:INVO) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that INVO Bioscience will report an earnings per share (EPS) of $-0.22.

INVO

4 minute read

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More

By Shanthi Rexaline

Today, 7:08 PM

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

ADMP